{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:41:06Z","timestamp":1786995666877,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Phytomedicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.phymed.2025.157760","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T23:33:51Z","timestamp":1767224031000},"page":"157760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Mechanism of d-Glucaro-1,4-lactone enhancing the anticancer efficacy of lenvatinib via the IFN-\u03b3-STAT3-PD-L1 signaling pathway in hepatocellular carcinoma"],"prefix":"10.1016","volume":"150","author":[{"given":"Yufeng","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiying","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyuan","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongrong","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dujuan","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0685-1346","authenticated-orcid":false,"given":"Baogang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phymed.2025.157760_bib0001","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00262-004-0593-x","article-title":"Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy","volume":"54","author":"Blank","year":"2005","journal-title":"Cancer Immunol. Immunther."},{"key":"10.1016\/j.phymed.2025.157760_bib0002","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1080\/17425255.2023.2272598","article-title":"Pharmacokinetic considerations for angiogenesis inhibitors used to treat hepatocellular carcinoma: an overview","volume":"19","author":"Borriello","year":"2023","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.phymed.2025.157760_bib0003","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.phymed.2025.157760_bib0004","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","article-title":"Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses","volume":"27","author":"Butte","year":"2007","journal-title":"Immunity."},{"key":"10.1016\/j.phymed.2025.157760_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2024.118569","article-title":"d-glucaro-1,4-lactone improves diethylnitrosamine induced hepatocellular carcinoma in rats via the uric acid-ROS pathway","volume":"334","author":"Cai","year":"2024","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.phymed.2025.157760_bib0006","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1002\/hep.28710","article-title":"Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features","volume":"64","author":"Calderaro","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.phymed.2025.157760_bib0007","article-title":"IL-2 modulates TAMs derived exosomal MiRNAs to ameliorate hepatocellular carcinoma development and progression","author":"Chen","year":"2022","journal-title":"J. Oncol."},{"key":"10.1016\/j.phymed.2025.157760_bib0008","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41419-020-03030-7","article-title":"AFP promotes HCC progression by suppressing the HuR-mediated Fas\/FADD apoptotic pathway","volume":"11","author":"Chen","year":"2020","journal-title":"Cell Death. Dis."},{"key":"10.1016\/j.phymed.2025.157760_bib0009","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jhep.2019.09.025","article-title":"Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma","volume":"72","author":"Cheng","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phymed.2025.157760_bib0010","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phymed.2025.157760_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1140849","article-title":"Differences in the pharmacokinetics and steady-state blood concentrations of orally administered lenvatinib in adult and juvenile rats","volume":"14","author":"Du","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phymed.2025.157760_bib0012","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jhep.2021.09.007","article-title":"NAFLD-driven HCC: safety and efficacy of current and emerging treatment options","volume":"76","author":"Foerster","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phymed.2025.157760_bib0013","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.phymed.2025.157760_bib0014","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.phymed.2025.157760_bib0015","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41392-020-00264-x","article-title":"Targeted therapy for hepatocellular carcinoma","volume":"5","author":"Huang","year":"2020","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.phymed.2025.157760_bib0016","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jhep.2021.08.012","article-title":"Epidemiology and risk-stratification of NAFLD-associated HCC","volume":"75","author":"Ioannou","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phymed.2025.157760_bib0017","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41586-021-03741-7","article-title":"EGFR activation limits the response of liver cancer to lenvatinib","volume":"595","author":"Jin","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.phymed.2025.157760_bib0018","article-title":"FAIL-T (AFP, AST, tumor sIze, ALT, and Tumor number): a model to predict intermediate-stage HCC patients who are not good candidates for TACE","volume":"10","author":"Kaewdech","year":"2023","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.phymed.2025.157760_bib0019","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.phymed.2025.157760_bib0020","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival","volume":"37","author":"Llovet","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.phymed.2025.157760_bib0021","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phymed.2025.157760_bib0022","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.phymed.2025.157760_bib0023","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s12253-019-00585-5","article-title":"Current status and perspective biomarkers in AFP negative HCC: towards screening for and diagnosing hepatocellular carcinoma at an earlier stage","volume":"26","author":"Luo","year":"2020","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.phymed.2025.157760_bib0024","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000346196","article-title":"Tumor-associated macrophage promotes tumor progression via STAT3 signaling in hepatocellular carcinoma","volume":"80","author":"Mano","year":"2013","journal-title":"Pathobiology"},{"key":"10.1016\/j.phymed.2025.157760_bib0025","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/cas.15719","article-title":"Lenvatinib enhances antitumor immunity by promoting the infiltration of TCF1(+) CD8(+) T cells in HCC via blocking VEGFR2","volume":"114","author":"Mei","year":"2023","journal-title":"Cancer Sci."},{"key":"10.1016\/j.phymed.2025.157760_bib0026","article-title":"Synergistic effect of IFN-\u03b3 and IL-1\u03b2 on PD-L1 expression in hepatocellular carcinoma","volume":"30","author":"Numata","year":"2022","journal-title":"Biochem. Biophys. Rep."},{"key":"10.1016\/j.phymed.2025.157760_bib0027","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10565-007-9028-8","article-title":"d-glucaro 1,4-lactone and resveratrol as antioxidants in blood platelets","volume":"24","author":"Olas","year":"2008","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.phymed.2025.157760_bib0028","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/cac2.12482","article-title":"Transcription factor ETV4 promotes the development of hepatocellular carcinoma by driving hepatic TNF-\u03b1 signaling","volume":"43","author":"Qi","year":"2023","journal-title":"Cancer Commun. (Lond)"},{"key":"10.1016\/j.phymed.2025.157760_bib0029","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1182\/blood-2018-01-829424","article-title":"Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer\/T-cell lymphoma","volume":"132","author":"Song","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.phymed.2025.157760_bib0030","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phymed.2025.157760_bib0031","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1084\/jem.192.2.303","article-title":"Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4","volume":"192","author":"Takahashi","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.phymed.2025.157760_bib0032","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.phymed.2025.157760_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101946","article-title":"Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma","volume":"82","author":"Vogel","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phymed.2025.157760_bib0034","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1021\/jf501744d","article-title":"Alteration of gut bacteria and metabolomes after glucaro-1,4-lactone treatment contributes to the prevention of hypercholesterolemia","volume":"62","author":"Xie","year":"2014","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.phymed.2025.157760_bib0035","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00216-014-8253-2","article-title":"Application of metabonomic strategy to discover an unreported active ingredient in LiuWeiDiHuang pills suppressing beta-glucuronidase","volume":"407","author":"Xie","year":"2015","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.phymed.2025.157760_bib0036","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/13880209.2018.1525414","article-title":"Metabonomics of d-glucaro-1,4-lactone in preventing diethylnitrosamine-induced liver cancer in rats","volume":"56","author":"Yang","year":"2018","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.phymed.2025.157760_bib0037","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1055\/s-0038-1676806","article-title":"Inflammation and liver cancer: molecular mechanisms and therapeutic targets","volume":"39","author":"Yang","year":"2019","journal-title":"Semin. Liver. Dis."},{"key":"10.1016\/j.phymed.2025.157760_bib0038","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/hep.31921","article-title":"Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-programmed cell death-1 in HCC","volume":"74","author":"Yi","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.phymed.2025.157760_bib0039","first-page":"25","article-title":"The role of interferon regulatory factors in liver diseases","author":"Zeng","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phymed.2025.157760_bib0040","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1038\/s41388-018-0303-3","article-title":"Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations","volume":"37","author":"ZERDES","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.phymed.2025.157760_bib0041","doi-asserted-by":"crossref","unstructured":"Zhao, T., Wei, P., Zhang, C., Zhou, S., Liang, L., Guo, S., Yin, Z., Cheng, S., Gan, Z., Xia, Y., Zhang, Y., Guo, S., Zhong, J., Yang, Z., Tu, F., Wang, Q., Bai, J., Ren, F., Feng, Z. & Jia, H. 2024. Nifuroxazide Suppresses PD-L1 Expression and Enhances the Efficacy of Radiotherapy in Hepatocellular Carcinoma. Elife, 12.","DOI":"10.7554\/eLife.90911"},{"key":"10.1016\/j.phymed.2025.157760_bib0042","article-title":"Trajectory and functional analysis of PD-1(high) CD4(+)CD8(+) T cells in hepatocellular carcinoma by single-cell cytometry and transcriptome sequencing","volume":"7","author":"Zheng","year":"2020","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.phymed.2025.157760_bib0043","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s12072-024-10696-0","article-title":"CBX1 is involved in hepatocellular carcinoma progression and resistance to sorafenib and lenvatinib via IGF-1R\/AKT\/SNAIL signaling pathway","volume":"18","author":"Zheng","year":"2024","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.phymed.2025.157760_bib0044","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.7754\/Clin.Lab.2018.180532","article-title":"Prognostic value of ALT, AST, and AAR in hepatocellular carcinoma with B-type Hepatitis-associated cirrhosis after radical hepatectomy","volume":"64","author":"Zhou","year":"2018","journal-title":"Clin. Lab."},{"key":"10.1016\/j.phymed.2025.157760_bib0045","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1200\/JCO.2013.53.7746","article-title":"SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma","volume":"33","author":"Zhu","year":"2015","journal-title":"J. Clin. Oncol."}],"container-title":["Phytomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711325013947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711325013947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T09:52:12Z","timestamp":1768557132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0944711325013947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":45,"alternative-id":["S0944711325013947"],"URL":"https:\/\/doi.org\/10.1016\/j.phymed.2025.157760","relation":{},"ISSN":["0944-7113"],"issn-type":[{"value":"0944-7113","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanism of d-Glucaro-1,4-lactone enhancing the anticancer efficacy of lenvatinib via the IFN-\u03b3-STAT3-PD-L1 signaling pathway in hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Phytomedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phymed.2025.157760","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"157760"}}